Project Name: Greater Manchester: MS Accelerating Patient Review for Improved Outcomes

Project Summary:

This collaborative working project aims to improve the capacity within the Collaborative Working (CW) Partner’s Multiple Sclerosis (MS) service in Greater Manchester through the expansion of the workforce to achieve the following;

  • A robust MS database. By cleansing the existing Greater Manchester MS database to ensure all MS patient records are coded appropriately.
  • A map of the MS patient pathway. By completing an MS service pathway mapping exercise to identify areas for improvement.
  • Reduce the referral to treatment (RTT). By triaging relapsing-remitting multiple sclerosis (RRMS) patients to ensure those who require a clinical review are seen in a timely manner.
  • Medicines optimisation. By reviewing and, where appropriate, providing treatment optimisation, for patients who are identified as requiring it.
  • Improve patient outcomes and experience by reducing the time between referral, diagnosis, and treatment.
  • Improving the future of the CW Partner’s MS service by ensuring patients on Low Efficacy Treatment (LET) or on no treatment but with active disease are managed appropriately.
  • Provide a proof of concept for sustainability of the MS service through service modelling and gathering relevant service metrics to help shape commissioning arrangements for the future of the service.

Planned Milestones:

MilestoneDescription
1

CW Partner & Novartis. 

  • Project kick off meeting 
2
  • CW Partner. 
  • Recruitment and onboarding of the project roles 
  • Baseline measurements submitted. 
3

CW Partner & Novartis. 

  • Pathway mapping.
  • Database audit and update.

CW Partner & Novartis. Project review meeting.

4-9

CW Partner. 3-month data collection and then every three months until 18-month data

CW Partner & Novartis. Project review meeting.

10

CW Partner. Project Outcomes Summary completed.

CW Partner & Novartis. Project wrap up meeting.

Expected Benefits:

Anticipated patient benefits;

  • Improved patient outcomes due to faster time from referral to treatment time.
  • Improved access to NICE recommended therapy.
  • Enhanced patient experience and satisfaction of the NHS MS service by reducing unnecessary waiting times.

Anticipated organisation benefits;

  • Appropriate use of skill set across the service.
  • Accelerated access to services.
  • Improved quality of care.
  • Reduction in patient waiting lists.
  • Improved MDT efficiency and outcomes.
  • Improved experience of staff by spreading workload.

Anticipated Novartis benefits;

  • Learnings relating to the involvement of MS DMT coordinator at MDTs.
  • Better understanding of overall customers’ and patients’ needs.
  • Optimal use of medicines (including Novartis medicines) in appropriate patients.

Start Date & Duration: January 2025 for 28 months

FA-11346756 | January 2025